💉 Vancomycin + pip–tazo associated with ⬆️risk of creatinine-defined #AKI in critically ill: pseudotoxicity?? No changes in alternative kidney function biomarkers, nor downstream clinical outcomes associated with true AKI (dialysis/mortality). #FOAMcc 📎 rdcu.be/cRLAi

As rated #2 by Dan YEOH at ASIDANZ #ASID22, fascinating paper in NEJM examining the use of Wolbachia infected A aegypti mosquitoes to reduce transmission of #Dengue in Indonesia. bit.ly/3ylw0Vp #IDTwitter #MedTwitter

😐 Evusheld 60-fold ⬇️ in neutralisation vs BA.5 ✅ Bebtelovimab retains neutralising activity vs BA.5 (not available outside US 🙁) ✅ Antivirals (remdesivir, molnupiravir, paxlovid) retain activity vs BA.5 ❌ Other monoclonal a/bs still dead in the water

Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase–Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections 🆓 Freely Available 🔗 bit.ly/3nRPvA7

This is intriguing!! Mycoplasma pneumoniae beyond the #COVID19 pandemic: where is it? #IDtwitter #medtwitter #TwitteRx #MedEd thelancet.com/journals/lanmi…

In the year after pandemic lockdowns, we saw an increased incidence of invasive pneumococcal disease in toddlers, higher than pre-pandemic levels because kids in the lockdown year remained susceptible after lockdown was lifted: CDC_EIDjournal …1/2 👉 wwwnc.cdc.gov/eid/article/28…

Timely study from NIH by Drs Susan Moir, Clarisa Buckner, Lela Kardava & colleagues “When the interval [between infection & booster] is too short, the response induced by the recent infection appears to prevent B cells from responding to the subsequent booster vaccine…”

Conventional wisdom is that previous infection with omicron subvariant BA.1 or BA.2 does notprotect against BA.5, but data from Portugal show considerable protection against BA.5 infection from previous BA.1 or BA.2 infection. nej.md/3pVDLxz

BREAKING: Very exciting news for our Hospital National Antimicrobial Prescribing Survey users. We have launched the Antifungal NAPS "deep dive" audit! Participate in the first national Antifungal NAPS audit and benchmark the quality of antifungal use in your patient population.

3. The ground is shaking beneath our feet- huge changes post-pandemic in RSV seasonality AND importantly susceptibility at Johns Hopkins University essentially no children under 17 months of age with RSV neutralising antibody!

Led by PhD candidate/ID physician Dan YEOH, an opportunity to harness the collective experience in diagnosing invasive pulmonary aspergillosis in Australian children - Timely diagnosis is key to improving outcomes Brendan McMullan monica slavin Gabrielle Haeusler link.springer.com/article/10.100…

#ECCMID2023 CONCERT trial for congenital CMV, most common inf. cause of hearing loss. Non-randomised small study but babies given 6 weeks of valgan did better than controls who had worse hearing - will be hard to recruit future placebo arms. Valerie Sung Gabrielle Haeusler NCIC

Multicentre study of IFI in paediatric acute leukaemia. Prov/Prob IFI remains high in ALL reflecting challenges of prophylaxis in this population. Great study Dan YEOH NCIC The Infection Flagship, MCRI, Melbourne telethonkids #ECCMID2023

With the current surge of severe #StrepA/GAS #infections in children worldwide, a timely article by The Infection Flagship, MCRI, Melbourne member Dr Josh Osowicki published in Journal of Infectious Diseases - this article definitely should be a contender for 'Title of the Year'! Murdoch Children's Research Institute (MCRI) 👏academic.oup.com/jid/article/22…

Just published! Large Australian cohort of #COVID19 affecting cancer patients. A big team effort… showing decreasing severity and all cause mortality over time. NCIC Tori Hall Beatrice Sim Ben Teh NCAS_Australia monica slavin doi.org/10.1016/j.lanw…

The SNAP Trial for Staphylococcus aureus bacteremia passed 2000 participants this month. We are now almost 2 years since opening. Beginning at one site and now at 93 sites in 8 countries. The 4th scheduled analysis planned for mid April. Joshua Davis Todd C. Lee Thread...

The drug that Australia spent most money on in 2022-2023? . . . . . . Molunupiravir AUD $650 million pbs.gov.au/statistics/exp…

Nice review from Dan YEOH and Gabrielle Haeusler highlighting >10% of children with AML develop fungal infections, and prophylaxis with novel therapies. Triazoles are the mainstay but newer agents have distinct advantages for children pubmed.ncbi.nlm.nih.gov/39110722 @MCRI_for_Kids @ANZPID #AMS

Dr Dan YEOH & colleagues on CT imaging of invasive mold infections in immunocompromised children: nodules & halo sign most common but no one feature predicts causative pathogen ➡️ microbiological sampling remains essential sciencedirect.com/science/articl… Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 #IDtwitter #IDxposts